Clinical Trials Logo

Clinical Trial Summary

This is a descriptive observational study, in which data are collected in an epidemiological fashion. This study does not intend to alter or intervene the current medical practice of the recruited patients. Data will be collected in prospective manner.


Clinical Trial Description

This is a descriptive observational study, in which data are collected in an epidemiological fashion. This study does not intend to alter or intervene the current medical practice of the recruited patients. Data will be collected in prospective manner.

The eligible patients will be recruited after NGS analysis for tumor tissue and the inform-consent is obtained. The study required information will be collected (every 3 months). ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03605602
Study type Observational [Patient Registry]
Source Guangdong Association of Clinical Trials
Contact Yi-Long Wu, Professor
Phone +86 20 83827812
Email syylwu@live.cn
Status Recruiting
Phase
Start date August 1, 2018
Completion date December 30, 2024

See also
  Status Clinical Trial Phase
Recruiting NCT03786692 - Phase II Randomized Trial of Carboplatin+Pemetrexed+Bevacizumab+/- Atezolizumab in Stage IV NSCLC Phase 2
Completed NCT04776083 - Radiotherapy to the Primary in Metastatic Non-small Cell Lung Cancer Patients Phase 3
Active, not recruiting NCT03288870 - Efficacy, Safety and Pharmacokinetics of BCD-100 (Anti-PD-1) Monotherapy as Second Line Treatment in Patients With Non-Small Cell Lung Cancer (DOMINUS) Phase 2/Phase 3
Recruiting NCT05919264 - FOG-001 in Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Recruiting NCT03042221 - Early Rebiopsy to Identify Biomarkers of Tumor Cell Survival Following EGFR, ALK, ROS1 or BRAF TKI Therapy
Recruiting NCT05274451 - A Study to Investigate LYL797 in Adults With Solid Tumors Phase 1
Recruiting NCT05372081 - Clinical and Molecular Study With Digital Support of Patients With Inoperable Lung Cancer
Recruiting NCT03774732 - PD-1 Inhibitor and Chemotherapy With Concurrent Irradiation at Varied Tumour Sites in Advanced Non-small Cell Lung Cancer Phase 3
Completed NCT03406468 - Re-Induction After Initial Response With Immune Therapy With Radiotherapy in Lung Cancer Phase 2
Recruiting NCT04856176 - A Study of Sargramostim Plus Pembrolizumab With or Without Pemetrexed in Patients With Advance Non-small Cell Lung Cancer After Completion of Chemoimmunotherapy Phase 2
Completed NCT04710459 - Endobronchial Cryotherapy in Management of MEBO in Patients With Inoperable NSCLC N/A
Terminated NCT02967133 - A Study of Nivolumab +/- Nab-paclitaxel in Non-small Cell Lung Cancer Phase 2